149 related articles for article (PubMed ID: 16164196)
1. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
[TBL] [Abstract][Full Text] [Related]
2. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
Abe K; Kosuda S; Kusano S
Ann Nucl Med; 2003 Dec; 17(8):649-55. PubMed ID: 14971606
[TBL] [Abstract][Full Text] [Related]
3. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
4. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
6. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
7. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
9. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Ann Nucl Med; 2002 Jun; 16(4):263-71. PubMed ID: 12126096
[TBL] [Abstract][Full Text] [Related]
10. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
11. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
14. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
Kanzaki R; Higashiyama M; Fujiwara A; Tokunaga T; Maeda J; Okami J; Kozuka T; Hosoki T; Hasegawa Y; Takami M; Tomita Y; Kodama K
Lung Cancer; 2011 Mar; 71(3):333-7. PubMed ID: 20619479
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
Nguyen VH; Peloquin S; Lacasse Y
Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
[TBL] [Abstract][Full Text] [Related]
18. Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma?
Sivrikoz CM; Ak I; Simsek FS; Döner E; Dündar E
Thorac Cardiovasc Surg; 2012 Mar; 60(2):116-21. PubMed ID: 21692019
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
